ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.

Asymchem Laboratories (Tianjin) Co., Ltd.

002821

CNE100002BZ6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
65.55 ^CNY	+1.60%		+7.14%	-43.54%

11/07	Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 107.91 Yuan From 118.48 Yuan, Keeps at Buy	MT
11/07	Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$76.45 From HK$83.94, Keeps at Buy	MT

Asymchem Laboratories Co., Ltd.(SZSE:002821) added to Shenzhen Stock Exchange Composite Index

January 11, 2017 at 10:30 am IST

Asymchem Laboratories (Tianjin) Co., Ltd. has been added to Shenzhen Stock Exchange Composite Index.

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 107.91 Yuan From 118.48 Yuan, Keeps at Buy	11/07	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$76.45 From HK$83.94, Keeps at Buy	11/07	MT
Asymchem Laboratories (Tianjin) Expects Up To 72% H1 Profit Drop; Shenzhen Shares Jump 9%	11/07	MT
Asymchem Laboratories Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2024	10/07	CI
Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	03/07	CI
Asymchem Appoints Cheng Yi Chen as CTO of Small-Molecule Sector	26/06	CI
Asymchem Laboratories Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 June 2024	25/06	CI
Asymchem Laboratories Co., Ltd. Approves Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 12 July 2024	06/06	CI
Asymchem Appoints Franck Mevellec as Senior Director, Business Development	29/05	CI
Asymchem Laboratories Buys Pfizer's Former UK Site; Hong Kong Shares Slide 3%	23/05	MT
China-Based Asymchem Laboratories Will Operate Former Pfizer Manufacturing Facility in UK	21/05	DJ
Asymchem Laboratories Co., Ltd. Secures Former Pfizer Sandwich, UK, Development and API Pilot Plant Manufacturing Facilities	21/05	CI
Asymchem Laboratories' Profit Drops 55%, Operating Income Slumps 38% in Q1; Shares Up 3%	29/04	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy	26/04	MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy	26/04	MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024.	02/04	CI
Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023	29/03	MT
Asymchem Laboratories Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023	28/03	CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Asymchem Laboratories Completes A-Share Repurchase Program	27/03	MT
Asymchem Laboratories Co., Ltd. commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024.	07/03	CI
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy	04/03	MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy	04/03	MT
Asymchem Laboratories Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024	29/02	CI

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Duration

Period

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

More charts

Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.

Sector

Pharmaceuticals

Calendar

19/07/2024 - Extraordinary Shareholders Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

65.55 CNY

Average target price

96.06 CNY

Spread / Average Target

+46.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.	-43.54%	3.05B
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals

Asymchem Laboratories (Tianjin) Co., Ltd.

Equities

002821

CNE100002BZ6

Pharmaceuticals

Asymchem Laboratories Co., Ltd.(SZSE:002821) added to Shenzhen Stock Exchange Composite Index

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals